Sulfone reverse hydroxamates as matrix metalloproteinase inhibitors

Author：

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.11, Iss.1, 2001-01, pp. : 133-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Advances in Studies on Hydroxamates as Matrix Metalloproteinase Inhibitors: A Review

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1704-1722

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclic sulfone hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α-converting enzymes

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 1, 2004-01 ,pp. : 121-124

Informa Healthcare

Access to resources Recommend Favorite

Matrix metalloproteinase inhibitors

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 10, 1997-10 ,pp. : 1213-1216

Informa Healthcare

Access to resources Recommend Favorite

Matrix metalloproteinase inhibitors and cancer

By Lauer-Fields J.L. Fields G.B.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 12, 2000-12 ,pp. : 1873-1884

Informa Healthcare

Access to resources Recommend Favorite

Matrix metalloproteinase inhibitors 1998

By Beckett R.P. Whittaker M.

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 3, 1998-03 ,pp. : 259-282

Informa Healthcare

Access to resources Recommend Favorite